JP2025507801A - 結晶性ｅｄｇ－２受容体拮抗薬を作製する方法 - Google Patents

結晶性ｅｄｇ－２受容体拮抗薬を作製する方法 Download PDF

Info

Publication number
JP2025507801A
JP2025507801A JP2024551569A JP2024551569A JP2025507801A JP 2025507801 A JP2025507801 A JP 2025507801A JP 2024551569 A JP2024551569 A JP 2024551569A JP 2024551569 A JP2024551569 A JP 2024551569A JP 2025507801 A JP2025507801 A JP 2025507801A
Authority
JP
Japan
Prior art keywords
compound
crystalline form
citric acid
formula
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507801A5 (enExample
Inventor
デニス ビレン，
ベネディクト マーティン，
ミシェル オマホニー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of JP2025507801A publication Critical patent/JP2025507801A/ja
Publication of JP2025507801A5 publication Critical patent/JP2025507801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024551569A 2022-03-02 2023-03-01 結晶性ｅｄｇ－２受容体拮抗薬を作製する方法 Pending JP2025507801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315898P 2022-03-02 2022-03-02
US63/315,898 2022-03-02
PCT/IB2023/000120 WO2023166346A1 (en) 2022-03-02 2023-03-01 Process of making a crystalline edg-2 receptor antagonist

Publications (2)

Publication Number Publication Date
JP2025507801A true JP2025507801A (ja) 2025-03-21
JP2025507801A5 JP2025507801A5 (enExample) 2026-03-10

Family

ID=86054291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551569A Pending JP2025507801A (ja) 2022-03-02 2023-03-01 結晶性ｅｄｇ－２受容体拮抗薬を作製する方法

Country Status (8)

Country Link
US (1) US12391640B2 (enExample)
EP (1) EP4486719A1 (enExample)
JP (1) JP2025507801A (enExample)
AU (1) AU2023228095A1 (enExample)
CA (1) CA3251849A1 (enExample)
MX (1) MX2024010565A (enExample)
TW (1) TW202346256A (enExample)
WO (1) WO2023166346A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391640B2 (en) 2022-03-02 2025-08-19 Horizon Therapeutics Ireland Dac Process of making a crystalline EDG-2 receptor antagonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571506A (en) 1989-08-14 1996-11-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
WO1992020350A1 (en) 1991-05-20 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
AU5300000A (en) 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
US20040026546A1 (en) 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
JPWO2001094309A1 (ja) 2000-06-02 2004-02-05 塩野義製薬株式会社 Ｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
CA2415900A1 (en) 2000-07-14 2002-01-31 The Uab Research Foundation Uses for nad synthetase inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP4223390B2 (ja) 2001-06-05 2009-02-12 エラン・ファルマ・インターナショナル・リミテッド 材料をフライス削りするシステムおよび方法
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
US20040157919A1 (en) 2002-01-25 2004-08-12 Yong-Qian Wu Trisubstituted carbocyclic cyclophilin binding compounds and their use
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1626742A1 (en) 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
US20090124654A1 (en) 2005-03-01 2009-05-14 Mjalli Adnan M M Aryl and Heteroaryl Compounds, Compositions, Methods of Use
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
PT2303270T (pt) 2008-05-05 2017-08-25 Sanofi Sa Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
CN112184094B (zh) 2019-07-03 2024-08-20 北京京东振世信息技术有限公司 一种地址信息采集方法和装置
KR20220161476A (ko) 2020-04-02 2022-12-06 호라이즌 테라퓨틱스 아일랜드 디에이씨 전신 경화증의 치료 방법
TW202227390A (zh) 2020-08-31 2022-07-16 法商賽諾菲公司 結晶型edg-2受體拮抗劑及製造方法
US12391640B2 (en) 2022-03-02 2025-08-19 Horizon Therapeutics Ireland Dac Process of making a crystalline EDG-2 receptor antagonist

Also Published As

Publication number Publication date
CA3251849A1 (en) 2023-09-07
WO2023166346A1 (en) 2023-09-07
EP4486719A1 (en) 2025-01-08
MX2024010565A (es) 2024-09-06
US12391640B2 (en) 2025-08-19
US20230295073A1 (en) 2023-09-21
TW202346256A (zh) 2023-12-01
AU2023228095A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
KR101881245B1 (ko) 오베티콜산의 제조법, 용도 및 고체 형태
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
KR20200131249A (ko) 항-염증제, 면역조절제 및 항-증식제로서의 신규한 칼슘 염 다형체
JP2020500925A (ja) ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の新規結晶形及びその製造方法
WO2014093583A2 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
JP2018501289A (ja) ネラチニブマレイン酸塩の新規な結晶形及びその製造方法
JP2024522603A (ja) （３ｒ）－ｎ－［２－シアノ－４－フルオロ－３－（３－メチル－４－オキソ－キナゾリン－６－イル）オキシ－フェニル］－３－フルオロ－ピロリジン－１－スルホンアミドの新規固形物
WO2020182978A1 (en) Crystalline salt of a 5-ht2a receptor antagonist
JP2025507801A (ja) 結晶性ｅｄｇ－２受容体拮抗薬を作製する方法
JP2024054139A (ja) Ｆｌｎａ結合化合物及びその塩酸塩の固体多形
TWI816690B (zh) 化合物的鹽及其晶型
JP2023545352A (ja) 結晶性ｅｄｇ－２受容体アンタゴニストおよび製造方法
JP2015164941A (ja) ９ｅ−１５−（２−ピロリジン−１−イル−エトキシ）−７，１２，２５−トリオキサ−１９，２１，２４−トリアザ−テトラシクロ［１８．３．１．１（２，５）．１（１４，１８）］ヘキサコサ−１（２４），２，４，９，１４，１６，１８（２６），２０，２２−ノナエンのクエン酸塩
TW202545917A (zh) Ｎ－［（１ｓ，２ｅ）－１－環丙基－３－（甲磺醯基）丙－２－烯－１－基］－２－（１，１－二氟乙基）－４－苯氧基嘧啶－５－甲醯胺的新固體形式
JP2025528904A (ja) Ｔｙｋ２阻害剤およびその使用
JP2025519705A (ja) Ｊａｋ阻害剤の固体形態及びその調製プロセス
WO2023192221A1 (en) Forms and compositions of sodium chenodeoxycholate
JP6907439B2 (ja) チエノピリミジン化合物の塩酸塩の結晶形
WO2015035817A1 (zh) 一种肌醇晶体及其制备方法和用途
CZ2016222A3 (cs) Pevné formy solí obeticholové kyseliny
KR20250026776A (ko) 고요산혈증 또는 통풍 치료 또는 예방을 위한 화합물의 고체 결정형
CN116529234A (zh) 结晶edg-2受体拮抗剂及制备方法
WO2017149332A1 (en) Mirabegron cocrystal
HK1254413A1 (en) Polymorphic crystalline forms of obeticholic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227